stoxline Quote Chart Rank Option Currency Glossary
Esperion Therapeutics, Inc. (ESPR)
1.58  0.08 (5.33%)    12-07 16:00
Open: 1.51
High: 1.5991
Volume: 2,142,974
Pre. Close: 1.5
Low: 1.5
Market Cap: 180(M)
Technical analysis
2023-12-07 4:20:26 PM
Short term     
Mid term     
Targets 6-month :  1.88 1-year :  2.19
Resists First :  1.61 Second :  1.88
Pivot price 1.32
Supports First :  1.14 Second :  0.85
MAs MA(5) :  1.52 MA(20) :  1.24
MA(100) :  1.23 MA(250) :  2.54
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  89.2 D(3) :  89.9
RSI RSI(14): 74
52-week High :  7.4 Low :  0.69
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ESPR ] has closed below upper band by 7.6%. Bollinger Bands are 50.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.6 - 1.61 1.61 - 1.61
Low: 1.48 - 1.49 1.49 - 1.5
Close: 1.57 - 1.58 1.58 - 1.59
Company Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Headline News

Tue, 05 Dec 2023
Is Esperion Therapeutics Inc (ESPR) a Good Buy in the Healthcare Sector? - InvestorsObserver

Tue, 05 Dec 2023
Do Analysts Expect Esperion Therapeutics Inc (ESPR) Stock to Rise After It Is Up 60.42% in a Month? - InvestorsObserver

Mon, 04 Dec 2023
Is Esperion Therapeutics Inc (ESPR) a Bad Choice in Drug Manufacturers - Specialty & Generic Monday? - InvestorsObserver

Thu, 30 Nov 2023
Is Esperion Therapeutics Inc (ESPR) a Stock to Watch After Gaining 11.57% This Week? - InvestorsObserver

Tue, 14 Nov 2023
Esperion Therapeutics, Inc.'s (NASDAQ:ESPR) Profit Outlook - Yahoo Finance

Wed, 08 Nov 2023
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2023 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers—Specialty & Generic
Shares Out 114 (M)
Shares Float 99 (M)
Held by Insiders 0.5 (%)
Held by Institutions 85.7 (%)
Shares Short 18,310 (K)
Shares Short P.Month 19,220 (K)
Stock Financials
EPS -2.27
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -3.67
Profit Margin -202.6 %
Operating Margin -81.1 %
Return on Assets (ttm) -36.5 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 79 %
Gross Profit (p.s.) -0.62
Sales Per Share 0.9
EBITDA (p.s.) -1.37
Qtrly Earnings Growth 0 %
Operating Cash Flow -141 (M)
Levered Free Cash Flow -114 (M)
Stock Valuations
PE Ratio -0.7
PEG Ratio -0.1
Price to Book value -0.44
Price to Sales 1.74
Price to Cash Flow -1.28
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android